Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. Its lead platform technology includes Progenza, a multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing. Regeneus Ltd was incorporated in 2007 and is headquartered in Paddington, Australia.

RGS

ASX:RGS

Regeneus Ltd

Last Close

0.01

09/04 05:59

Market Cap

3.68M

Beta: −0.28

Volume Today

4.28M

Avg: 480.41K

PE Ratio

−0.42

PFCF: -

Filings Not Available